Table 2.
Change in hemodynamics versus baseline catheterization
| All (N = 34) | Q1 (2–5 mg) | Q2 (6–6.5 mg) | Q3 (7.75–10 mg) | Q4 (10.25–16 mg) | |
|---|---|---|---|---|---|
| RAP, mmHg | −0.2 ± 7 | −3 ± 8 | 2 ± 8 | −1 ± 4 | 0 ± 6 |
| PAP, mmHg | 1 ± 8 | 2 ± 7 | 5 ± 5a | 0 ± 7 | −4 ± 12 |
| PCWP, mmHg | 0.9 ± 5 | 0 ± 6 | 2 ± 4 | −1 ± 3 | 3 ± 5 |
| CI, L/min/m2 (N = 33)a | 0.1 ± 0.7 | 0 ± 0.4 | −0.2 ± 0.5 | 0.3 ± 0.9 | 0.2 ± 0.7 |
| SVo2, % | −2 ± 8 | −3 ± 8 | −5 ± 10 | −3 ± 6 | 3 ± 6 |
| PVR, Wood units (N = 33)a | 0.01 ± 3.6 | 0.7 ± 2.4 | 1.2 ± 3 | −0.1 ± 2.2 | −2.3 ± 5.2 |
| Daily treprostinil dose, mg | 7.8 ± 3.6 | 3.8 ± 1.3 | 6.3 ± 0.3 | 8.8 ± 0.8 | 12.9 ± 2 |
| Median daily treprostinil dose, mg | 6.5 | 3.5 | 6.25 | 8.75 | 13.125 |
Data are reported as mean ± standard deviation unless otherwise specified. First follow-up catheterization was performed after 11 ± 7 months of therapy. Three patients (9%) received add-on PDE5i or ERA therapy before follow-up. Missing data are due to clinical worsening and catheterization before 3 months of therapy (N = 1), medication discontinuation without catheterization (N = 1), or insurance issues (N = 1). No comparisons were statistically significant. CI: cardiac index; ERA: endothelin 1 receptor antagonist; PAP: pulmonary arterial pressure; PCWP: pulmonary capillary wedge pressure; PDE5i: phosphodiesterase type 5 inhibitor; PVR: pulmonary vascular resistance; Q: dosing quartile; RAP: right atrial pressure; SVo2: mixed venous oxygen saturation.
N = 33 because baseline CI data were missing for 1 patient.